TP53 and plasma cell myeloma: Deletion of 17p leads to a dismal outcome in MM-patients and “double-hit” myelomas, with a concurrent mutation in the other allele having a particularly bad prognosis, suggesting a high relevance of the p53-pathway in MM [25,27].